Coagulation factor XII (Hageman factor) Washington D.C.: inactive factor XIIa results from Cys-571----Ser substitution.
AUTOR(ES)
Miyata, T
RESUMO
Structural studies on a congenital abnormal coagulation factor XII (Hageman factor), factor XII Washington D.C., have been performed to identify the defect responsible for its lack of procoagulant activity. Amino acid sequence analysis of a tryptic peptide isolated from the abnormal factor XII indicated that Cys-571 (equivalent to Cys-220 in the chymotrypsin numbering system) had been replaced by serine. No other substitutions in the active-site triad--namely, His-393, Asp-442, and Ser-544--were found. We propose that the Cys-571----Ser replacement found in this factor XII variant destroys the formation of the disulfide linkage between Cys-540 and Cys-571, giving rise to an altered conformation of the active-site serine residue or the secondary substrate-binding site and, thus, leads to the loss of enzyme activity.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=298272Documentos Relacionados
- cDNA sequence coding for human coagulation factor XII (Hageman).
- Mitogenic effects of coagulation factor XII and factor XIIa on HepG2 cells.
- Role of surface in surface-dependent activation of Hageman factor (blood coagulation Factor XII)
- CONTRIBUIÇÃO AO ESTUDO DA PROGRAMAÇÃO D.C.: DIFERENÇA DE DUAS FUNÇÕES CONVEXAS
- TWO INTERNATIONAL MEETINGS IN WASHINGTON, D.C
